Condition: Metastatic Clear Cell Renal Cell Carcinoma · Sponsor: Jinling Hospital, China
The purpose of this study is to evaluate the safety and feasibility of a treatment holiday strategy directed by CD70-targeted immuno-PET/CT in patients with metastatic clear cell renal cell carcinoma (mccRCC). Specifically, the study aims to assess whether patients who achieve both anatomical disease control and metabolic response after 12 months of first-line PD-1/PD-L1 ICI + VEGFR-TKI combination therapy can safely pause their treatment, improve quality of life without compromising therapeutic efficacy.
This description comes directly from the study's public registry record.
Le Qu, Ph.D. · +86 15720625951 · septsoul@hotmail.com
Always discuss trial participation with your own doctor first.
| Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University | Nanjing, Jiangsu, China | Recruiting |
| Nanjing First Hospital, Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| The First Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| Sir Run Run Hospital, Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| Wuxi No.2 People's Hospital (Jiangnan University Medical Center) | Wuxi, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07615348